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1748-6815/ª 2014 British Association of PSummary Hypertrophic scars and keloids can be aesthetically displeasing and lead to severe
psychosocial impairment. Many invasive and non-invasive options are available for the plastic
(and any other) surgeon both to prevent and to treat abnormal scar formation. Recently, an
updated set of practical evidence-based guidelines for the management of hypertrophic scars
and keloids was developed by an international group of 24 experts from a wide range of spe-
cialities.
An initial set of strategies to minimize the risk of scar formation is applicable to all types of
scars and is indicated before, during and immediately after surgery. In addition to optimal sur-
gical management, this includes measures to reduce skin tension, and to provide taping, hy-
dration and ultraviolet (UV) protection of the early scar tissue. Silicone sheeting or gel is
universally considered as the first-line prophylactic and treatment option for hypertrophic
scars and keloids. The efficacy and safety of this gold-standard, non-invasive therapy has been
demonstrated in many clinical studies. Other (more specialized) scar treatment options are
available for high-risk patients and/or scars. Pressure garments may be indicated for more
widespread scarring, especially after burns. At a later stage, more invasive or surgicalof Plastic Surgery, Ghent University Hospital, De Pintelaan, 185, B-9000 Ghent, Belgium. Tel.: þ32 93
ent.be (S. Monstrey).
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1018 S. Monstrey et al.procedures may be necessary for the correction of permanent unaesthetic scars and can be
combined with adjuvant measures to achieve optimal outcomes.
The choice of scar management measures for a particular patient should be based on the
newly updated evidence-based recommendations taking individual patient and wound charac-
teristics into consideration.
ª 2014 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by
Elsevier Ltd. All rights reserved.Table 1 Overview of non-invasive and invasive treat-
ments for scars.
Non-invasive treatment Invasive treatment
 Well-accepted, evidence-based,
and recommended treatments
 Pressure/compression
therapy
 Intralesional
corticosteroid
injection
 Silicone sheets and gels  Surgical scar correction
 Investigational treatments and
those with less supporting evidence
 Oils, lotions and creams  Laser therapy
 Massage therapy  Radiotherapy
 Static and dynamic splints  Cryosurgery
 Psychological counselling  Intralesional injection of
other products
 Antihistamine drugsIntroduction
Plastic surgeons play an important role in both the pre-
vention and the treatment of unaesthetic scar formation
following operations, trauma, burns or infections. Esti-
mates indicate that each year around 100 million people in
the developed world acquire scars following elective sur-
gery and surgery for trauma.1 Of these, approximately 15%
have excessive or unaesthetic scars.1 Scarring can also be a
major source of dissatisfaction after a purely cosmetic
surgical procedure such as aesthetic breast surgery.2
Furthermore, a recent survey indicated that 91% of pa-
tients who underwent a routine surgical procedure would
value any improvement in scarring.3
Excessive scarring can have unpleasant physical,
aesthetic, psychological and social consequences. Physical
symptoms may include itching, stiffness, scar contractures,
tenderness and pain.4,5 The psychosocial effects of unaes-
thetic scarring include diminished self-esteem, stigmati-
zation, disruption of daily activities, anxiety and
depression.5e7
There is a wide spectrum of cutaneous scarring ranging
from mature linear scars to abnormal raised and wide-
spread hypertrophic scars and major keloids. Hypertrophic
scars stay within the boundaries of the original lesion and
may spontaneously regress with time.8,9 Hypertrophic scars
can be classified as linear or widespread with the former
usually resulting from surgery or trauma, and the latter
from burn injuries or extensive soft tissue trauma and/or
infections. Keloids are excessive scars that grow beyond the
boundaries of the original wound. They do not spontane-
ously regress and frequently recur after being excised.8,9
Keloids can be differentiated into minor or major with
the latter being large, raised (>0.5 cm) scars that may be
painful, pruritic and protruding. Histologically, there are
additional differences between hypertrophic scars and ke-
loids. For example, hypertrophic scars primarily contain
well-organized type III collagen, whereas keloids contain
disorganized type I and III collagen bundles.10 Although
existing strategies for the management of hypertrophic
scars and keloids are broadly similar, these histological
differences suggest that, in the future, therapeutic ap-
proaches could be developed which are specifically tailored
for these different types of scars.
Currently, a wide variety of different scar management
measures has been advocated both to prevent and to treat
unaesthetic or excessive scar formation (Table 1). Recently,
an international, multidisciplinary group of 24 experts
developed a set of practical, evidence-based guidelines forthe management of linear, hypertrophic and keloid scars
which could be useful for surgeons, dermatologists, general
practitioners and other physicians involved in the preven-
tion and the treatment of scars.11 The panel developed
these guidelines after reviewing new clinical and evidence-
based data on scar management that have been reported
since the publication of a previous set of guidelines by the
International Advisory Panel on Scar Management in 2002.12
This review article is intended to provide surgeons and
other physicians with an overview of the most relevant in-
formation from the updated guidelines. Whilst there are
many published review articles on treatment approaches
for hypertrophic scars and keloids, the current article is
different in that it presents these new guidelines and dis-
cusses the most relevant aspects for surgeons. In particular,
specific surgical techniques that are of benefit in both the
prevention and treatment of scars are discussed.
The literature cited in this article includes the most
relevant publications that were used to develop the recent
evidence-based guidelines.11 In addition, PubMed was
searched using terms including ‘scar prevention’, ‘scar
treatment’, ‘hypertrophic scar’, ‘keloid’, ‘silicone’,
‘intralesional corticosteroid’, ‘pressure therapy’, ‘laser
therapy’, ‘radiotherapy’ and ‘cryotherapy’ to identify
additional studies and review articles on scar management
that are of particular relevance to surgeons. Whilst this
article is not a systematic literature review of treatment
options for scar management, we do refer interested
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for more extensive lists of supporting references.11
Scar Management Practical Guidelines
A summary of the updated guidelines on the practical
management of linear scars, widespread hypertrophic scars
and keloids is shown in Figure 1. The recommendations are
discussed more in detail below with an emphasis both on
universal preventive strategies applicable to every scar and
on more invasive and specialized treatment of excessive
scar formation.
Scar prevention
Following surgery or trauma, the first priority should always
be the prevention of abnormal scar formation. In the case
of an operative procedure, scar prevention measures
should be initiated during or even before surgery. InFigure 1 Practical guidelines for the management of linear (A),
with the permission of Maca-Cloetens from ‘Scar Management Pracelective surgery, the position and the length of the incision
line should be carefully considered and if possible should
always be parallel to the relaxed skin tension lines.
Excessive scar formation can also be prevented by a wide
range of measures that reduce inflammation and provide
rapid wound closure such as early debridement of dead
tissue, reducing the risk of infection through rinsing and
disinfection, and optimal dressings providing moist wound
healing and/or early surgical wound coverage.11,13 During
the operation, the surgeon should also ensure that exces-
sive tension on the wound edges is avoided.
The three major components of scar prevention imme-
diately after wound closure are as follows: (1) tension re-
lief, (2) hydration/taping/occlusion, and (3) pressure
garments. Wounds which have greater tension on their
edges, e.g., those perpendicular to Langer’s lines, and
those in the deltoid and sternal regions have a higher risk of
developing excessive scarring,14 which can be reduced by
the use of post-surgical taping for a 3-month period.15 More
recently, Gurtner et al. investigated the role of mechanicalwidespread hypertrophic (B) and keloid scars (C). Reproduced
tical Guidelines’.
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shielding device in reducing mechanical stress and pre-
venting excessive scar formation.16 The device was made
from silicone polymer sheets and pressure-sensitive adhe-
sive and was applied to wounds immediately after skin
closure. Studies in both animals and humans demonstrated
that offloading mechanical forces with the stress-shielding
device significantly reduced scar formation.16 In addition,
botulinum toxin A decreases tensile forces on post-surgical
scars and results in significant improvements in the
cosmetic appearances of scars compared with placebo
injections.17
Moisturizing emollient and humectant creams and
moisture-retentive dressings such as silicone sheets and
fluid silicone gel have been shown to be beneficial for
itching scars, and can also reduce the size and pain or
discomfort associated with scars as well as improving their
appearance. Studies have shown that, after wound healing,
water still evaporates more rapidly through scar tissue and
may take over a year to recover to pre-wound levels.18
Silicone products may help to prevent excessive scar for-
mation by restoring the water barrier through occlusion and
hydration of the stratum corneum and need to be used as
soon as the wound/suture is healed.19
In patients with more widespread scars, such as after
burns, pressure garments may also be used prophylactically
in wounds that take >2e3 weeks to heal spontaneously
with the device being applied as soon as the wound is
closed and the patient can tolerate the pressure.11,20
Other strategies are currently under investigation for
the prevention of scarring such as altering the levels of
certain inflammatory cytokines such as transforming growth
factor (TGF)-b3. This cytokine reduces connective tissue
deposition and is mainly produced towards the end of the
wound healing process.10 Initial clinical studies of avo-
termin, a human recombinant TGF-b3, have indicated that
this treatment may reduce scar formation following full-
thickness skin incisions.21
Additional general preventive measures for all types of
scars recommended in the latest guidelines (Figure 1(AeC))
include avoiding exposure to sunlight and the continued use
of sunscreens with a high to maximum sun protection factor
(>50) until the scar has matured.11 Randomized studies in
animals and humans have shown that ultraviolet radiation
increases scar pigmentation and worsens their clinical
appearance.22,23
As a general rule, scars should always be re-evaluated
4e8 weeks after surgery to determine whether additional
scar management interventions are required or whether
preventive therapy can be terminated.11Linear hypertrophic scars
The guidelines recommend that the preventive therapy as
described above is continued or intensified in patients who
develop early hypertrophy in their linear scar at 6 weeks to
3 months after surgery or trauma.11 Pressure therapy may
be initiated if this has not yet been applied.
If there is further scar maturation 6 months after surgery
or trauma, silicone therapy should be continued for as long
as necessary. In patients with ongoing hypertrophy, moreinvasive measures are indicated such as the use of intra-
lesional corticosteroids. This is the only invasive manage-
ment option which currently has enough supporting
evidence to be recommended in evidence-based guide-
lines.11,12 The most commonly used corticosteroid is
triamcinolone acetonide 10e40 mg/mL which should be
injected into the papillary dermis every 2e4 weeks
until the scar is flattened.8 Between 50% and 100% of pa-
tients respond to this treatment with 9e50% experiencing
recurrence.24 Excessive pain during injections can lead
to non-compliance with the treatment. Other side
effects include skin atrophy, hypopigmentation and
telangiectasias.8,25
Although the likelihood of developing hypertrophic scars
is often thought to be greater in children than in the elderly
with much more time required for their scars to mature,
there is hardly any evidence to support this in the litera-
ture.26 Despite the fact that there are very few studies on
the technique of corticosteroid injections in children, most
experts agree that this technique is not contraindicated in
these young patients, but that dose adaption to the child’s
weight is advised to avoid systemic exposure.27,28 The
corticosteroid injection should always be limited to the scar
itself and injection into the periscar tissues must be avoi-
ded as this may cause underlying fat atrophy irrespective of
a patient’s age.29
Additional injectable treatment options which may help
to treat hypertrophic scars (and keloids) include bleomycin,
5-fluorouracil and verapamil, although the evidence to
support these is currently more limited than for intrale-
sional corticosteroids.11,30e32 Bleomycin is thought to work
by decreasing collagen synthesis and, in a study of 50 pa-
tients, was shown to adequately flatten hypertrophic scars
and keloids in 80% of patients.30 5-Fluorouracil inhibits
fibroblast proliferation and has been shown to be an
effective treatment for inflamed hypertrophic scars.31 A
combination of 5-fluorouracil and triamcinolone acetonide
may be more effective at treating scars than the individual
treatments.31,33,34 For example, this combination was
associated with significantly greater reductions in scar size
and erythema compared with triamcinolone acetonide
alone in a 12-week double-blind study of 40 patients.34
Verapamil is a calcium channel antagonist which both de-
creases collagen synthesis and increases collagen break-
down. In a randomized, single-blind study of 54 patients
with hypertrophic scars or keloids, scar vascularity,
pliability, height and width were reduced with intralesional
verapamil, although the rate of reduction in these param-
eters was slower than with intralesional triamcinolone.32 A
scar contracture is an abnormal shrinkage or shortening of a
non-matured scar that can result in functional impairment
and is often seen in combination with scar hypertrophy.
Surgical correction of a scar contracture with a Z-plasty, a
skin graft or a flap may be indicated at an early stage to
release tension in the scar which eventually restores
function and at the same time reduces scar hypertrophy.
If the patient develops a permanent (>1 year) hyper-
trophic scar, surgical scar revision may be considered.35,36
Aesthetic correction of linear hypertrophic scars is usually
done by simple resection and primary closure together with
a type of tension-releasing technique such as undermining
and approximation of the wound edges, subcutaneous
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silicone gels after wound closure.35Widespread hypertrophic scars
Early application of silicone and compression therapy is
essential for patients who are at a risk of widespread hy-
pertrophic scars following burns, mechanical trauma or
necrotizing infections. Pressure and silicone therapy should
be routinely applied in every wound that takes >2e3 weeks
to heal or after skin grafting, and should be given as soon as
the wound is closed and the patient can tolerate
pressure.11,20
Pressure therapy has recently been considered as an
‘evidence-based’ modality for the treatment of scars.20
The mechanism of its action remains poorly understood
despite its widespread use around the world. Part of the
effect of pressure could involve reduction of oxygen tension
in the wound through occlusion of small blood vessels
resulting in a decrease of (myo)fibroblast proliferation and
collagen synthesis.37
Recent studies underline the critical role of cellular
mechanoreceptors in the high success rate of compression
therapy. Mechanoreceptors are involved in cellular
apoptosis and are linked to the extracellular matrix. It is
conceivable that increased pressure via the matrix regu-
lates apoptosis of dermal fibroblasts and diminishes the
hypertrophic process.38 In addition, through the process of
mechanotransduction, sensory nerve cells transduce me-
chanical pressure into intracellular biochemical and gene
expression, thus synthesizing and releasing different cyto-
kines that may play a role in the physiopathogenesis of
proliferative scarring.39
Finally, besides these causative effects, pressure ther-
apy can also provide symptomatic treatment benefits such
as the alleviation of oedema, itchiness and pain which may
contribute to the patient’s well-being.40
The initial treatment of pressure and silicone therapy
should be continued or intensified in patients with ongoing
hypertrophy. Localized corticosteroid injections can also be
indicated to treat the more excessive parts of hypertrophic
scars and these can be supplemented with bleomycin, 5-
fluorouracil and/or verapamil as appropriate.11,30,31,33,41
These therapies should preferably be reserved for use in
specialized centres in which there is a greater degree of
expertise.
Laser therapy is another invasive option which can be
used to treat the surface texture of abnormal scars and may
also be suitable for the treatment of residual redness,
telangiectasias or hyperpigmentation.11 Vrijman et al., in a
recent meta-analysis, demonstrated scientific evidence
only for the pulsed dye laser (PDL) 585 and not for the
intense pulsed light (IPL), the non-ablative fractional laser
(NAFL) 1550 nm, the CO2 ablative fractional laser (AFL), the
532-nm laser and the 2940-nm erbium laser.42 Since the
publication of this meta-analysis, a case series has been
published confirming the efficacy of the PDL, especially in
combination with occlusion/compression and intralesional
corticosteroids.43 In addition, there have also been several
positive reports on the NAFL 1550 nm and the CO2 AFL.
44e46
Various other lasers have also been used in the treatment ofscars: Nd:YAG long pulse 1064 nm,47 Q-switch Nd:YAG,48
light-emitting diodes (LEDs) and photodynamic therapy
(PDT).49 Finally, laser therapy has also been advocated for
the prevention or minimization of both post-surgical and
traumatic scars, and even in combination with botulinum
toxin.50 Although more clinical evidence on the use of la-
sers is needed, both for the choice of the device as well as
for the settings/treatment schedules, the increasing num-
ber of articles being published on the successful manage-
ment of hypertrophic scars with lasers is increasing the
interest in this therapeutic modality.
As mentioned previously, early surgery is always indi-
cated in the case of contractures with functional impair-
ment. Contracture release after burns in areas such as the
neck and axilla are best performed with flaps rather than
with skin grafts as flaps usually develop minimal secondary
contraction and therefore produce excellent functional and
aesthetic results.
Long-standing or permanent widespread hypertrophic
scars may be treated surgically, sometimes using the same
techniques as for permanent linear hypertrophic scars. For
larger scars, serial excision or skin stretching may be indi-
cated which involves the advancement of adjacent skin by
sufficient undermining after resection of the central part of
the scar.11,51 Subcutaneous sutures are needed to relieve
the tension from the overlying skin given that this proce-
dure involves stretching the skin. Surgical skin replacement
(resurfacing) of unaesthetic widespread scars may be per-
formed using autologous skin grafts.52 Dermal substitutes
may also be used for skin resurfacing in patients with
extensive skin trauma such as those with severe burns.53
Tissue expansion is also a very helpful technique for surgi-
cal scar correction, especially for reconstruction of the
scalp. These surgical reconstruction procedures should
ideally be performed in dedicated specialized centres.Keloids
Keloids are also best treated in centres with specialized
expertise. Patients with growing minor or major keloids
should first be treated with silicones in combination with
pressure therapy and intralesional injections of cortico-
steroids.11 Intralesional 5-fluorouracil, bleomycin and
verapamil can also be considered, preferably in accordance
with existing treatment protocols.8,11,30,31,41,54 If the keloid
does not respond to 12 months of these treatments, then
surgical excision should be considered always in combina-
tion with some form of adjuvant therapy as surgical exci-
sion alone has been associated with a high recurrence rate
of 50e100% and may even result in enlargement of the
keloid.8 Some experts recommend that the lateral parts of
keloids should not be excised, but should be joined
together and left in situ. However, others have objected to
this proposal and consider that the cells from these lateral
parts of the keloid are more active in terms of collagen
production.55
The combination of scar resection and immediate post-
operative radiotherapy was proposed many years ago, and
both electron beam irradiation and brachytherapy with
iridium 192 can be used after surgical removal of the keloid
to reduce recurrence rates.56 Many objections have been
1022 S. Monstrey et al.raised concerning the potential side effects of post-
operative radiotherapy, especially regarding the potential
risk of inducing malignancy. However, on the basis of an
extensive review of literature on this subject, Ogawa et al.
concluded that the risk of malignancy attributable to keloid
radiation therapy is minimal.57
An additional promising new invasive treatment modal-
ity for keloids is internal cryotherapy in which a metal rod is
introduced into the keloid and the subsequent extreme
cooling leads to tissue necrosis.58 In a study of 10 patients,
scar volume was significantly reduced by 54% after one
intralesional treatment with no recurrence over an 18-
month follow-up period.58
Finally, imiquimod 5% is a topical immune response
modifier which stimulates the production of interferon
leading to increased collagen breakdown. Some studies
have reported low recurrence rates of 0e29% following
surgical excision of keloids and subsequent topical appli-
cation of imiquimod 5% cream.59,60 However, other studies
have reported that imiquimod 5% cream is not effective at
preventing keloid recurrence with recurrence rates of
89%.61First-line non-invasive scar management: more
evidence on the role of silicone therapy
The latest guidelines for scar management advocate sili-
cone therapy as a non-invasive first-line prophylactic and
treatment option for both hypertrophic scars and keloids.11
Indeed, of the non-invasive options, silicone sheets and
silicone gels are universally considered as the gold standard
in scar management and the only non-invasive preventive
and therapeutic measure for which there is enough sup-
porting data to make evidence-based recommendations.12
Silicone therapy is an attractive alternative to more inva-
sive treatment options as it is easy to use and is associated
with only minimal side effects such as pruritus, contact
dermatitis and dry skin.62 This therapy is believed to pre-
vent and treat scars through occlusion and subsequent hy-
dration of the scar tissue.19
Silicone sheeting consists of a soft, semi-occlusive gel
sheet made from medical-grade silicone that is reinforced
with a silicone membrane backing to give the sheet
increased durability and ease of handling. Some sheets use
a combination of silicone and Teflon (polytetrafluoro-
ethylene) to create ultra-thin, flexible and durable
sheeting. Patients may be reluctant to use the sheeting on
exposed areas of the body, and compliance with treatment
is a frequent concern.63
Recently, fluid silicone gel formulations have been
developed using the same basic long-chain silicone polymer
that is used in silicone sheeting. This more recent formu-
lation of silicone for scar treatment was specifically
developed to overcome some of the problems encountered
with silicone gel sheets such as the need for fixation and
difficulties in using sheets on large areas or near joints as
well as on exposed areas such as the face and hands. The
fluid silicone gel is applied in a thin layer to the skin where
it dries to form a transparent, flexible, gas-permeable,
water-impermeable silicone sheet. Similar to silicone
sheeting, silicone gels should not be applied to openwounds and can be used for as long as the patient derives
benefit.
The pivotal role of silicone sheeting for the prevention
and treatment of hypertrophic scars and keloids resulting
from many types of trauma, including burns and surgical
excisions, has been established in many clinical studies with
all but one showing positive effects.63e71 A meta-analysis
found that silicone sheeting reduces the incidence of hy-
pertrophic scarring in high-risk individuals compared with no
treatment (response rate: 0.46; 95% confidence interval
0.21e0.98).72 Recent data have also shown that silicone
sheeting can be used in combination with pressure therapy
producing better improvements in post-traumatic hyper-
trophic scars than either therapy alone. The two treatments
have complementary modes of action with the silicone
therapy acting on the erythema and pliability of the scar,
whereas the pressure therapy prevents scar thickening.73
Several clinical studies have indicated the beneficial
effects of silicone gels in the prevention and treatment of
scars.74e78 Several comparative studies with silicone sheets
have shown that fluid silicone gels have at least equivalent
efficacy although patients may find the gel formulations
easier to use.78,79
Conclusions
Unaesthetic scarring is associated with physical and psy-
chosocial consequences. Plastic surgeons play an essential
role in minimizing scar formation after elective surgery and
in correcting unaesthetic scars once matured. Choices
regarding appropriate scar management measures should
be guided by the clinical recommendations provided in this
consensus article, but should also be tailored to individual
patient and wound requirements. Preventive measures are
a major priority and need to be applied before, during and
immediately after wound closure. Treatment of hypertro-
phic scars, contractures and keloids is generally based on
reducing mechanical tension in the scar, removal of the
bulky scar tissue by reconstructive surgical techniques and/
or injection of substances that promote collagen break-
down in situ. Silicone sheets and gels are recommended as
the ‘gold standard’, non-invasive therapies for both the
prevention and the treatment of hypertrophic scars and
keloids with gels being preferred by patients. These prod-
ucts can be used in combination with other invasive and
non-invasive treatment options to provide patients with
optimal outcomes.
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